The company says precision medicine has advanced in cancer and rare disease but common-disease care still relies on one-size-fits-all trials that are large, costly, and prone to late-stage failure. Its $30 million Series A backs an AI-and-genetic-testing network for healthcare systems and biopharma intended to identify genetically defined patients, improve care, and make clinical trials more efficient.